MapLight Therapeutics (MPLT) Income from Continuing Operations (2024 - 2025)
MapLight Therapeutics recorded quarterly Income from Continuing Operations of 80907000.0 in Q4 2025, down 170.15% quarter-over-quarter from 29949000.0 in Q3 2025, and down 269.81% year-over-year from 47645644.69 in Q4 2024.
MapLight Therapeutics' Income from Continuing Operations history runs 2 years deep, the most recent figure standing at 80907000.0 for Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 269.81% year-over-year to 80907000.0; the TTM figure through Dec 2025 stood at 152547000.0 (changed N/A YoY), while the FY2025 annual figure was 163565000.0, down 108.52% from the prior year.
- Income from Continuing Operations came in at 80907000.0 for Q4 2025 at MapLight Therapeutics, down from 29949000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 19813000.0 in Q3 2024 to a low of 80907000.0 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | MapLight Therapeutics | 254.43 Mn | 254.43 Mn | - | -80.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -80.91 Mn |
| Sep 30, 2025 | -29.95 Mn |
| Dec 31, 2024 | -21.88 Mn |
| Sep 30, 2024 | -19.81 Mn |